6Fabin CJ,Molina R,Slavik M,et al.Pyridoxine therapy for palmarplantar erythrodysesthesia associated with continouous 5-fluorouracil infusion[J].Invest New Drugs,1990,8:57-63.
二级参考文献29
1孙燕.抗肿瘤新药的临床试用方法[J].中华肿瘤杂志,1980,2:150-150.
2Miwa M,Nishidaum,Ishikawa ST,et al.Disign of a novel oral fluoropy rimidine carbamate capelitabine which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and Cancer[J].Eur J Carcer,1998,34(8):1274
3Schueller J,Cassidy,Dumont E,et al.preferential ac ivation of Capecitabine in tumor following oral adminstration to colorectal patients[J].Cancer Chemother Pharmacol,2000,45(2):291
4孙燕.临床肿瘤内科手册[M].第4版.北京:人民卫生出版社,2001.591-592
5Koizumi W, Saigenji K, Nakamaru N,et al. Prediction of response to 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor [J]. Oncology,1999;56(3) :215-222.
6Takiguchi N, Nakajima N, Saitoh N, et al. A phase Ⅲ randomized study comparing oral doxifluridine and oral 5-fluorouracil after curative resection of gastric cancer[J]. Int J Oncol, 2000 , 6 (5): 1021-1027.
7Miyadera K, Sumizawa T, Haraguchi M, et al . Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase[J]. Cancer Res,1995,55(8): 1687-1690.
8Maeda K, Chung YS, Ogawa Y, et al. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma[J]. Br J Cancer, 1996,73 (8): 884-888.
9Mata JF, Garcia Manteiga JM, Lostao MP, et al. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5 [Prime] - deoxy- 5- fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug[J ]. Mol Pharmacol,2001,59(6): 1542.
10Miwa M, UraM, NishidaM, etal. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue[J]. Eur J Cancer, 1998,34(8) :1274-1281.
4Fabin C J, Nolina R, Slavik M, et al. Pyridoxine therapy for palmarplantar erythredyseathesia associated with continouous 5 - fluorouracil in fusion [ J ]. Invest New Drugs, 1990,8:57 - 63.
5Van Cutsem E, Twelves C, Cassidy J, et al. Oral eapecitibine compared with intravenous fluoronrail plus leucovpfin in patients with metastatic colorectal cancer:results of a large phase III study[J]. J Clin Oncol,2001,19 :4097 - 4106.
6Talbot De, Moiseyenko V, VanBell S, et al. Randomised, phase Ⅱ trial comparing oral capecitabine (xeioda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthrancyclin [ J]. Br J CanceR,2002,86 : 1367 - 1372.
7Chua DT,Sham JS,Au GK. A phase Ⅱ study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum - based chemotherapy [ J ]. oral ontology, 2003,39:361 - 366.
8陈灏珠.实用内科学[M].北京:人民卫生出版社,2009.
9Kang Y,Lee J,Min Y,et al.A randomized multicenter phase Ⅱ trail of capecitabine(X) versus S-1(S) as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer:2007ASCO Annual Meeting Proceedings[J].J Clin Oncol,2007,25:4546.
10Soreide K,Janssen E,Koner H,et al.Trypsin in colorectal cancer molecular biological mechanisms of proliferation invasion and metastasis[J].J Pathol,2006,209(2):147-156.
